Drug profile · INN
framycetin sulfate + gramicidin + dexamethasone
OTODEX
framycetin sulfate + gramicidin + dexamethasone (OTODEX) is a glucocorticoid receptor agonist. Associated with Lacuna Pharma Pty Ltd.
TGA: approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — framycetin sulfate + gramicidin + dexamethasone
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.81
Quick answer
framycetin sulfate + gramicidin + dexamethasone (OTODEX) is a glucocorticoid receptor agonist. Associated with Lacuna Pharma Pty Ltd.
Key facts
INN framycetin sulfate + gramicidin + dexamethasone
Brand OTODEX
Mechanism Glucocorticoid receptor agonist
Target Glucocorticoid receptor
Originator Lacuna Pharma Pty Ltd
Mechanism of action
Glucocorticoid receptor agonist
Primary target: Glucocorticoid receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| TGA | approved | — |
Related & competitor drugs
Frequently asked questions
What is framycetin sulfate + gramicidin + dexamethasone?
framycetin sulfate + gramicidin + dexamethasone (OTODEX) is a glucocorticoid receptor agonist. Associated with Lacuna Pharma Pty Ltd.
What is the brand name for framycetin sulfate + gramicidin + dexamethasone?
OTODEX is a marketed brand name for framycetin sulfate + gramicidin + dexamethasone. Check FDA Drugs@FDA for the current US label holder and prescribing information.